PR
NTLA icon

PSP Research’s Intellia Therapeutics NTLA Stock Holding History

PSP Research’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Sell
20,000
-6,900
-26% -$96.6K 0.18% 43
2026
Q1 		$345K Buy
+26,900
New +$343K 0.24% 55

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

PSP Research's NTLA Position: Q2 2026 in Review

PSP Research reduced its Intellia Therapeutics (NTLA) stake by 26% in Q2 2026, selling an estimated $96.6K and leaving 20,000 shares worth $338K. The position accounts for 0.18% of the portfolio, ranked #43.

PSP Research first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. The position peaked at $345K in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • PSP Research held 20,000 shares of Intellia Therapeutics worth $338K as of Q2 2026.
  • PSP Research sold 6,900 Intellia Therapeutics shares in Q2 2026, an estimated $96.6K.
  • Intellia Therapeutics made up 0.18% of PSP Research's portfolio in Q2 2026, its #43 holding.
  • PSP Research first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • PSP Research's Intellia Therapeutics position peaked at $345K in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.